CH675833A5 - - Google Patents
Download PDFInfo
- Publication number
- CH675833A5 CH675833A5 CH2943/88A CH294388A CH675833A5 CH 675833 A5 CH675833 A5 CH 675833A5 CH 2943/88 A CH2943/88 A CH 2943/88A CH 294388 A CH294388 A CH 294388A CH 675833 A5 CH675833 A5 CH 675833A5
- Authority
- CH
- Switzerland
- Prior art keywords
- wound
- carrier
- active ingredient
- preparation according
- polymer
- Prior art date
Links
- 208000027418 Wounds and injury Diseases 0.000 claims description 36
- 206010052428 Wound Diseases 0.000 claims description 34
- 229920000642 polymer Polymers 0.000 claims description 20
- 229960001380 cimetidine Drugs 0.000 claims description 18
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 18
- 230000029663 wound healing Effects 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- 229920002307 Dextran Polymers 0.000 claims description 11
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 10
- 239000011324 bead Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims description 8
- 239000004744 fabric Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 5
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 5
- 229960000620 ranitidine Drugs 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 2
- 230000008961 swelling Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 20
- 235000019441 ethanol Nutrition 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000000969 carrier Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229930002875 chlorophyll Natural products 0.000 description 3
- 235000019804 chlorophyll Nutrition 0.000 description 3
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229960002304 thenalidine Drugs 0.000 description 2
- KLOHYVOVXOUKQI-UHFFFAOYSA-N thenalidine Chemical compound C1CN(C)CCC1N(C=1C=CC=CC=1)CC1=CC=CS1 KLOHYVOVXOUKQI-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000012260 Accidental injury Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- SWECWXGUJQLXJF-BTJKTKAUSA-N Dimetindene maleate Chemical compound OC(=O)\C=C/C(O)=O.CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 SWECWXGUJQLXJF-BTJKTKAUSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- FPBPLBWLMYGIQR-UHFFFAOYSA-N Metiamide Chemical compound CNC(=S)NCCSCC=1N=CNC=1C FPBPLBWLMYGIQR-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- MVMQESMQSYOVGV-UHFFFAOYSA-N dimetindene Chemical compound CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 MVMQESMQSYOVGV-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229950003251 metiamide Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960003534 phenindamine Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002984 plastic foam Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/436—Inhibitors, antagonists of receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU873554A HU201683B (en) | 1987-08-04 | 1987-08-04 | Process for producing pharmaceutical compositions for promoting healing of wounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH675833A5 true CH675833A5 (enrdf_load_stackoverflow) | 1990-11-15 |
Family
ID=10964527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH2943/88A CH675833A5 (enrdf_load_stackoverflow) | 1987-08-04 | 1988-08-03 |
Country Status (16)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1002406A5 (fr) * | 1988-09-20 | 1991-01-29 | Glaxo Group Ltd | Compositions pharmaceutiques. |
| IT1241521B (it) * | 1990-07-31 | 1994-01-17 | Polifarma Spa | Impiego teperautico della ranitidina nella cura di ferite interessantila cute e i tessuti sottostanti |
| GB9102660D0 (en) * | 1991-02-07 | 1991-03-27 | Ultra Lab Ltd | Wound dressing materials |
| DE4220736A1 (de) * | 1992-06-25 | 1994-01-05 | Puetter Medice Chem Pharm | Einschlußkomplexe aus polymerisierten Cyclodextrinen mit pharmazeutisch aktiven Wirkstoffen |
| GB9424562D0 (en) * | 1994-12-06 | 1995-01-25 | Giltech Ltd | Product |
| DE9420259U1 (de) * | 1994-12-17 | 1995-02-09 | Röhm GmbH, 64293 Darmstadt | Entbittertes Ranitidin-Präparat |
| HUP9904362A3 (en) * | 1996-08-16 | 2000-12-28 | Schering Corp | Treatment of upper airway allergic responses with a combination of histamine h1 and h3 receptor antagonists |
| US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
| JP2001139477A (ja) * | 1999-11-17 | 2001-05-22 | Coherent Technology:Kk | 創傷部位の組織細胞増殖促進液 |
| MXPA04006438A (es) | 2001-12-31 | 2005-06-08 | Ares Lab Llc | Composiciones hemostaticas y metodos para el control de sangrado. |
| DE10355085A1 (de) * | 2003-11-24 | 2005-06-23 | Schure, Frank, Dr. | Wundverband |
| CN103816560B (zh) * | 2014-03-03 | 2015-06-24 | 广西南宁博恩康生物科技有限公司 | 一种用于创口修复的胶体液及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE452109B (sv) * | 1973-01-29 | 1987-11-16 | Pharmacia Ab | Rengoringsmedel for vetskande utvertes sarytor |
| US4747845A (en) * | 1983-10-17 | 1988-05-31 | Enquay Pharmaceutical Associates | Synthetic resin matrix system for the extended delivery of drugs |
| US4668228A (en) * | 1985-03-12 | 1987-05-26 | Johnson & Johnson Products, Inc. | Debriding tape |
| IE58373B1 (en) * | 1986-06-18 | 1993-09-08 | Bloomfield Frederick Jacob | 5-Lipoxygenase pathway inhibitors |
-
1987
- 1987-08-04 HU HU873554A patent/HU201683B/hu not_active IP Right Cessation
-
1988
- 1988-08-02 BG BG85119A patent/BG49522A1/xx unknown
- 1988-08-03 CH CH2943/88A patent/CH675833A5/de not_active IP Right Cessation
- 1988-08-03 FR FR8810477A patent/FR2619011A1/fr active Pending
- 1988-08-03 SE SE8802805A patent/SE8802805L/xx not_active Application Discontinuation
- 1988-08-03 BE BE8800899A patent/BE1001932A4/fr not_active IP Right Cessation
- 1988-08-03 NL NL8801930A patent/NL8801930A/nl not_active Application Discontinuation
- 1988-08-03 DD DD88318589A patent/DD272414A5/de not_active IP Right Cessation
- 1988-08-03 CS CS543688A patent/CS274600B2/cs unknown
- 1988-08-03 DE DE3826419A patent/DE3826419A1/de not_active Withdrawn
- 1988-08-03 IT IT8821634A patent/IT1226586B/it active
- 1988-08-03 AU AU20387/88A patent/AU612387B2/en not_active Ceased
- 1988-08-03 FI FI883638A patent/FI883638A7/fi not_active Application Discontinuation
- 1988-08-03 ES ES8802427A patent/ES2007544A6/es not_active Expired
- 1988-08-03 JP JP63192899A patent/JPH01117828A/ja active Pending
- 1988-08-04 GB GB8818575A patent/GB2207865B/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| GB2207865B (en) | 1991-10-09 |
| AU612387B2 (en) | 1991-07-11 |
| CS543688A2 (en) | 1990-10-12 |
| BE1001932A4 (fr) | 1990-04-17 |
| DE3826419A1 (de) | 1989-02-16 |
| HU201683B (en) | 1990-12-28 |
| ES2007544A6 (es) | 1989-06-16 |
| IT8821634A0 (it) | 1988-08-03 |
| NL8801930A (nl) | 1989-03-01 |
| JPH01117828A (ja) | 1989-05-10 |
| FR2619011A1 (fr) | 1989-02-10 |
| DD272414A5 (de) | 1989-10-11 |
| IT1226586B (it) | 1991-01-24 |
| FI883638L (fi) | 1989-02-05 |
| FI883638A0 (fi) | 1988-08-03 |
| FI883638A7 (fi) | 1989-02-05 |
| BG49522A1 (en) | 1991-12-16 |
| GB8818575D0 (en) | 1988-09-07 |
| SE8802805D0 (sv) | 1988-08-03 |
| SE8802805L (sv) | 1989-02-05 |
| HUT47848A (en) | 1989-04-28 |
| CS274600B2 (en) | 1991-08-13 |
| AU2038788A (en) | 1989-02-09 |
| GB2207865A (en) | 1989-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69032125T2 (de) | Gelwundverbandszusammensetzungen und verfahren zu deren gebrauch | |
| DE102006001954B4 (de) | Antiseptische Alginatzubereitung, Verfahren zu deren Herstellung, sowie deren Verwendung | |
| DE69206407T2 (de) | Wundverband. | |
| DE2403269C2 (enrdf_load_stackoverflow) | ||
| EP0040378B1 (de) | Mischung für halbstarre medizinische Stützverbände, damit erhaltene medizinische Binde und Verfahren zu deren Herstellung | |
| DE69214732T2 (de) | Heilender Wundverband | |
| DE60008790T2 (de) | Medizinische verbände enthaltend gelartigen honig | |
| DE3011664A1 (de) | Wundverband | |
| CH672598A5 (enrdf_load_stackoverflow) | ||
| WO1992003172A1 (de) | Wundauflagensystem | |
| EP1593399A2 (de) | Bioresorbierbare Wundauflage auf Kollagen-Basis | |
| DE212012000057U1 (de) | Antimikrobielles Gemisch und eine antimikrobiell wirkende Abdeckung zur Unterstützung der Wundheilung | |
| CH675833A5 (enrdf_load_stackoverflow) | ||
| DE69029969T2 (de) | Kunsthaut | |
| DE3586569T2 (de) | Verband und verfahren zu seiner herstellung. | |
| DE3240909A1 (de) | Zubereitung zur wundheilung und verfahren zu ihrer herstellung | |
| DE69426385T2 (de) | Präparate für die Wundheilung, die Iod und einen Zucker enthalten | |
| CH615099A5 (enrdf_load_stackoverflow) | ||
| DE2412128A1 (de) | Chirurgischer verband und verfahren zur bildung desselben in situ | |
| CH668179A5 (de) | Zweischicht-folienumschlag und verfahren zu dessen herstellung. | |
| DE69533658T2 (de) | Wundverband | |
| DE3631413A1 (de) | Therapeutisches system zur lokalen applikation von pharmawirkstoffen | |
| DE202023100113U1 (de) | Dreidimensional vernetztes Hydrogel | |
| EP3687587B1 (de) | Pastöse zubereitung zur bildung eines halbstarrverbands | |
| EP0209142A2 (de) | Mittel zur Behandlung von Schürf-, Brand- und sonstigen Wunden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |